Plasma cholesteryl ester transfer protein (CETP) in relation to human pathophysiology

The HDL Handbook

Volumn , Issue , 2010, Pages 35-59

  Inazu, Akihiro ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84856208700     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-382171-3.10003-8     Document Type: Chapter

References (124)

1. Agellon L.B., Quinet E.M., Gillette T.G., Drayna D.T., Brown M.L., Tall A.R. Organization of the human cholesteryl ester transfer protein gene. Biochemistry 1990, 29:1372-1376.
2. Agerholm-Larsen B., Nordestgaard B.G., Steffensen R., Jensen G., Tybjaerg-Hansen A. Elevated HDL cholesterol is a risk fator for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 2000, 101:1907-1912.
3. Ai M., Tanaka A., Shimokado K., et al. A deficiency of cholesteryl ester transfer protein whose serum remnant-like particle (RLP)-triglyceride significantly increased, but RLP-cholesterol did not after an oral fat load. Ann Clin Biochem 2009, 46:457-463.
4. Arias-Vasquez A., Isaacs A., Aulchenko Y.S., et al. The cholesteryl ester transfer protein (CETP) gene and the risk of Alzheimer's disease. Neurogenetics 2007, 8:189-193.
5. Asztalos B., Horvath K.V., Kajinami K., et al. Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency. J Lipid Res 2004, 45:448-455.
6. Bailhache E., Briand F., Nguyen P., Krempf M., Magot T., Ouguerram K. Metabolism of cholesterol ester of apolipoprotein B100-containing lipoproteins in dogs: evidence for disregarding cholesterol ester transfer. Eur J Clin Invest 2004, 34:527-534.
7. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109-2122. for the ILLUMINATE Investigators.
8. Barter P.J., Lally J.I. The activity of an esterified cholesterol transferring factor in human and rat serum. Biochim Biophys Acta 1978, 531:233-236.
9. Barzilai N., Atzmon G., Schechter C., et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. J Am Med Assoc 2003, 290:2030-2040.
10. Bisgaier C.L., Siebenkas M.V., Brown M.L., et al. Familial cholesteryl ester transfer protein deficiency is associated with triglyceride-rich low density lipoproteins containing cholesteryl esters of probable intracellular origin. J Lipid Res 1991, 32:21-33.
11. Bloomfield D., Carlson G.L., Sapre A., et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009, 157:352-360.
12. Borggreve S.E., Hillege H.L., Dallinga-Thie G.M., et al. High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides. Eur Heart J 2007, 28(8):1012-1018. on behalf of the PREVEND Study Group.
13. Brousseau M.E., Diffenderfer M.R., Millar J.S., et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 2005, 25:1-8.
14. Brousseau M.E., Schaefer E.J., Wolfe M.L., et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004, 350:1505-1515.
15. Brown M.L., Inazu A., Hesler C.B., et al. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 1989, 342(6248):448-451.
16. Catalano G., Julia Z., Frisdal E., et al. Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway. Arterioscler Thromb Vasc Biol 2009, 29:268-275.
17. Cazita P.M., Barbeiro D.F., Moretti A.I.S., Quitao E.C.R., Soriano F.G. Human cholesteryl ester transfer protein expression enhances the mouse survival rate in an experimental systemic inflammation model: a novel role for CETP. Shock 2008, 30:590-595.
18. Cheema S.K., Agarwal-Mawal A., Murray C.M., Tucher S. Lack of stimulation of cholesteryl ester transfer protein by cholesterol in the presence of a high-fat diet. J Lipid Res 2005, 46:2356-2366.
19. Chen D.W., Yang J.F., Tang Z., et al. Cholesteryl ester transfer protein polymorphism D442G associated with a potential decreased risk for Alzheimer's disease as a modifier for APOE e{open}4 in Chinese. Brain Res 2008, 1187:52-57.
20. Cheung M.C., Wolfbauer G., Albers J.J. Plasma phospholipids mass transfer rate: relationship to plasma phospholipid and cholesteryl ester transfer activities and lipid parameters. Biochim Biophys Acta 1996, 1303:103-110.
21. Chiba H., Akita H., Tsuchihashi K., et al. Quantitative and compositional changes in high density lipoprotein subclasses in patients with various genotypes of cholesteryl ester transfer protein deficiency. J Lipid Res 1997, 38:1204-1216.
22. Chien K.L., Sung F.C., Hsu H.C., Su T.C., Lin R.S., Lee Y.T. Apolipoprotein A-I and B and stroke events in a community-based cohort in Taiwan. Report of the Chin-Shan Community Cardiovascular Study. Stroke 2002, 33:39-44.
23. Curb J.D., Abbott R.D., Rodriguez B.L., et al. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res 2004, 45:948-953.
24. Dallinga-Thie G.M., Dullaart R.P.F., van Tol A. Concerted actions of cholesteryl ester transfer protein and phospholipid transfer protein in type 2 diabetes: effects of apolipoproteins. Curr Opin Lipidol 2007, 18:251-257.
25. Davidson W.S., Silva R.A.G.D., Chantepie S., Lago W.R., Chapman M.J., Kontush A. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters. Arterioscler Thromb Vasc Biol 2009, 29:870-876.
26. Drayna D., Jarnagin A.S., McLean J., et al. Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature 1987, 327:632-634.
27. Dullaart R.P.F., de Vries R., Scheek L., et al. Type 2 diabetes mellitus is associated with differential effects on plasma cholesteryl ester transfer protein and phospholipid transfer protein activities and concentrations. Scand J Clin Lab Invest 2004, 64:205-216.
28. Fournier N., Paul J.L., Atger V., et al. HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum. Arterioscler Thromb Vasc Biol 1997, 17:2685-2691.
29. Gautier T., Klein A., Deckert V., et al. Effect of plasma phospholipid transfer protein deficiency on lethal endotoxemia in mice. J Biol Chem 2008, 283:18702-18710.
30. Gofman J.W., Young W., Tandy R. Ischemic heart disease, atherosclerosis, and longevity. Circulation 1966, 34:679-697.
31. Gotoda T., Kinoshita M., Ishibashi S., et al. Skipping of exon 14 and possible instability of both the mRNA and the resultant truncated protein underlie a common cholesteryl ester transfer protein deficicency in Japan. Arterioscler Thromb Vasc Biol. 1997, 17:1376-1381.
32. Guerin M., Bruckert E., Dolphin P.J., Turpin G., Chapman M.J. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 1996, 16:763-772.
33. Ha Y.C., Barter P.J. Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species. Comp Biochem Physiol 1982, 71B:265-269.
34. Haraki T., Inazu A., Yagi K., Kajinami K., Koizumi J., Mabuchi H. Clinical characteristics of double heterozygotes with familial hypercholesterolemia and cholesteryl ester transfer protein deficiency. Atherosclerosis 1997, 132:229-236.
35. Hayashi H., Campenot R.B., Vance D.E., Vance J.E. Apolipoprotein E-containing lipoproteins protect neurons from apoptosis via a signaling pathway involving low-density lipoprotein receptor-related protein-1. J Neurosci 2007, 27:1933-1941.
36. Hernandez M., Wright S.D., Cai T.Q. Critical role of cholesterol ester transfer protein in nicotinic acid-mediated HDL elevation in mice. Biochem Biophys Res Commun 2007, 355:1075-1080.
37. Hudgins L.C., Parker T.S., Levine D.M., et al. A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers. J Lipid Res 2003, 44:1489-1498.
38. Hussain M.M., Innerarity T.L., Brecht W.J., Mahley R.W. Chylomicron metabolism in normal, cholesterol-fed, and Watanabe heritable hyperlipidemic rabbits. J Biol Chem 1995, 270:8578-8587.
39. Ikewaki K., Nishiwaki M., Sakamoto T., et al. Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency. J Clin Invest 1995, 96:1573-1581.
40. Ikewaki K., Rader D.J., Sakamoto T., et al. Delayed catabolism of high density lipoprotein apolipoprotein A-I and A-II in human cholesteryl ester transfer protein deficiency. J Clin Invest 1993, 92:1650-1658.
41. Inazu A., Brown M.L., Hesler C.B., et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990, 323(18):1234-1238.
42. Inazu A., Jiang X.C., Haraki T., et al. Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. J Clin Invest 1994, 94(5):1872-1882.
43. Inazu A., Koizumi J., Kajinami K., Kiyohara T., Chichibu K., Mabuchi H. Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma. Atherosclerosis 1999, 145(2):405-413.
44. Inazu A., Nakajima K., Nakano T., et al. Decreased post-prandial triglyceride response and diminished remnant lipoprotein formation in cholesteryl ester transfer protein (CETP) deficiency. Atherosclerosis 2008, 196:953-957.
45. Inazu A., Quinet E.M., Wang S., et al. Alternative splicing of the mRNA encoding the human cholesteryl ester transfer protein. Biochemistry 1992, 31(8):2352-2358.
46. Jansen H., Verhoeven A.J.M., Sijbrands E.J.G. Hepatic lipase: a pro- or anti-atherogenic protein?. J Lipid Res 2002, 43:1352-1362.
47. Jeon S.M., Park Y.B., Kwon O.S., et al. Vitamin E supplementation alters HDL-cholesterol and paranoxase activity in rabbits fed high cholesterol diet: comparison with probucol. J. Biochem Molecular Taxicology 2005, 19:336-346.
48. Jeppesen J., Hein H.O., Suadicani P., Gyntelberg F. Triglyceride concentration and ischemic heart disease. An eight-year follow-up in the Copenhagen Male Study. Circulation 1998, 97:1029-1036.
49. Kastelein J.J.P., van Leuven S.I., Burgess L., et al. Effects of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007, 356:1620-1630. for the RADIANCE 1 Investigators.
50. Kee P., Caiazza D., Rye K.A., Barrett P.H.R., Morehouse L.A., Barter P.J. Effects of inhibiting cholesteryl ester transfer protein on the kinetics of high-density lipoprotein cholesteryl ester transport in plasma. In vivo studies in rabbits. Arterioscler Thromb Vasc Biol 2006, 26:884-890.
51. Keys A. Lipoprotein profile - its value in prediction. Prev Med 1983, 12:25-31.
52. Kiyohara T., Kiriyama R., Zamma S., Inazu A., Koizumi J., Mabuchi H., Chichibu K. Enzyme immunoassay for cholesteryl ester transfer protein in human serum. Clin Chim Acta 1998, 271(2):109-118.
53. Koizumi J., Inazu A., Yagi K., et al. Serum lipoprotein lipid concentration and composition in homozygous and heterozygous patients with cholesteryl ester transfer protein deficiency. Atherosclerosis 1991, 90(2-3):189-196.
54. Koizumi J., Mabuchi H., Yoshimura A., et al. Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. Atherosclerosis 1985, 58:175-186.
55. Kontush A., de Faria E.C., Chantepie S., Chapman M.J. Antioxidative activity of HDL particle subspecies is impaired in hyperalphalipoproeinemia: Relevance of enzymatic and physicochemical properties. Arterioscler Thromb Vasc Biol 2004, 24:526-533.
56. Kontush A., Therond P., Zerrad A., et al. Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles. Arterioscler Thromb Vasc Biol 2007, 27:1843-1849.
57. Koropatnick T.A., Kimbell J., Chen R., et al. A prospective study of high-density lipoprotein cholesterol, cholesteryl ester transfer protein gene variants, and healthy aging in very old Japanese-American men. J Gerontol 2008, 63A:1235-1240.
58. Krimbou L., Marcil M., Chiba H., Genest J. Structural and functional properties of human plasma high density-sized lipoprotein containing only apoE particles. J Lipid Res 2003, 44:884-892.
59. Kurth T., Everett B.M., Buring J.E., Kase C.S., Ridker P.M., Gaziano J.M. Lipid levels and the risk of ischemic stroke in women. Neurology 2007, 68:556-562.
60. Lamarche B., Uffelman K.D., Carpentier A., et al. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apoA-I in healthy men. J Clin Invest 1999, 103:1191-1199.
61. Lee J.Y., Badeau R.M., Mulya A., et al. Functional LCAT deficiency in human apolipoprotein A-I transgenic, SR-BI knockout mice. J Lipid Res 2007, 48:1052-1061.
62. Leppala J.M., Paunio M., Virtamo J., et al. Alcohol consumption and stroke incidence in male smokers. Circulation 1999, 100:1209-1214.
63. Levels J.H.M., Pajkrt D., Schultz M., et al. Alterations in lipoprotein homeostasis during human experimental endotoxemia and clinical sepsis. Biochim Biophys Acta 2007, 1771:1429-1438.
64. Li L., Thompson P.A., Kitchens R.L. Infection induces a positive acute phase apolipoprotein E response from a negative acute phase gene: role of hepatic LDL receptors. J Lipid Res 2008, 49:1782-1793.
65. Lu H., Inazu A., Moriyama Y., et al. Haplotype analyses of cholesteryl ester transfer protein gene promoter: a clue to an unsolved mystery of TaqIB polymorphism. J Mol Med 2003, 81(4):246-255.
66. Luo Y., Tall A.R. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest 2000, 105:513-520.
67. MacLean P.S., Bower J.F., Vadlamudi S., et al. Cholesteryl ester transfer protein expression prevents diet-induced atherosclerosis lesions in male db/db mice. Arterioscler Thromb Vasc Biol 2003, 23:1412-1415.
68. MacLean P.S., Vadlamudi S., MacDonald K.G., Pories W.J., Barakat H.A. Suppression of hepatic cholesteryl ester transfer protein expression in obese humans with the development of type 2 diabetes mellitus. J Clin Endocrinol Metab 2005, 90:2250-2258.
69. Mahley R.W., Innerarity T.L., Weisgraber K.H., Fry D.L. Canine hyperlipoproteinemia and atherosclerosis. Am J Pathol 1977, 87:205-226.
70. Manabe M., Abe T., Nozawa M., Maki A., Hirata M., Itakura H. New substrate for determination of serum lecithin:cholesterol acyltransferase. J Lipid Res 1987, 28:1206-1215.
71. Masson D., Staels B., Gautier T., et al. Cholesteryl ester transfer protein modulates the effect of liver X receptor agonists on cholesterol transport and excretion in the mouse. J Lipid Res 2004, 45:543-550.
72. Millar J.S., Brousseau M.E., Diffenderfer M.R., et al. Effects of cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans. Arterioscler Thromb Vasc Biol 2006, 26:1350-1356.
73. Miwa K., Inazu A., Kawashiri M., et al. Cholesterol efflux from J774 macrophages and Fu5AH hepatoma cells to serum is preserved in CETP-deficient patients. Clin Chim Acta 2009, 402:19-24.
74. Miyazaki O., Fukamachi I., Mori A., et al. Formation of prebeta1-HDL during lipolysis of triglyceride-rich lipoprotein. Biochem Biophys Res Commun 2009, 379:55-59.
75. Moriyama Y., Okamura T., Inazu A., et al. A low prevalence of coronary heart disease in subjects with increased high-density lipoprotein cholesterol levels including those with plasma cholesteryl ester transfer protein deficiency. Prev Med 1998, 27(5Pt1):659-667.
76. Musliner T.A., Long M.D., Forte T.M., Krauss R.M. Size transformations of intermediate and low density lipoproteins induced by unesterified fatty acids. J Lipid Res 1991, 32:903-915.
77. Nagano M., Nakamura M., Kobayashi N., Kamata J., Hiramori K. Effort angina in a middle-aged woman with abnormally high levels of serum high-density lipoprotein cholesterol. Circ J 2005, 69:609-612.
78. Nagano M., Yamashita S., Hirano K.I., et al. Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese. J Atheroscler Thromb 2004, 11:110-121.
79. Nagasaki T., Akanuma Y. A new colorimetric method for the determination of plasma lecithin-cholesterol acyltransferase activity. Clin Chim Acta 1977, 75:371-375.
80. Nissen S.E., Tardif J.C., Nicholls S.J., et al. Effects of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007, 356:1304-1316. for the ILLUSTRATE Investigators.
81. Okamura-Noji K., Sasai K., Zhan R., et al. Cholesteryl ester transfer protein deficiency causes slow egg embryonation of Schistosoma japonicum. Biochim Biophys Res Commun 2001, 286:305-310.
82. Oliveira H.C.F., Ma L., Milne R., et al. Cholesteryl ester transfer protein (CETP) activity enhances plasma cholesteryl ester formation: studies in CETP transgenic mice and human genetic CETP deficiency. Arterioscler Thromb Vasc Biol 1997, 17(6):1045-1052.
83. Ordovas J.M., Cupples L.A., Corella D., et al. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol. 2000, 20(5):1323-1329.
84. Ouguerram K., Nguyen P., Krempf M., et al. Selective uptake of high density lipoproteins cholesteryl ester in the dog, a species lacking in cholesteryl ester transfer protein activity. An in vivo approach using stable isotopes. Comparative Biochem Physiol, Part B 2004, 138:339-345.
85. Pattnaik N.M., Montes A., Hughes L.B., Zilversmit D.B. Cholesteryl ester exchange protein in human plasma isolation and characterization. Biochim Biophys Acta 1978, 530:428-438.
86. Pruneta V., Pulcini T., Lalanne F., et al. VLDL-bound lipoprotein lipase facilitates the cholesteryl ester transfer protein-mediated transfer of cholesteryl esters from HDL to VLDL. J Lipid Res 1999, 40:2333-2339.
87. Qiu X., Mistry A., Ammirati M.J., et al. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nature Struct Molec Biol 2007, 14(2):106-113.
88. Regieli J.J., Jukema J.W., Grobbee D.E., et al. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur Heart J 2008, 29:2792-2799.
89. Rhyne J., Ryan M.J., White C., Chimonas T., Miller M. The two novel CETP mutations Gln87X and Gln165X in a compound heterozygous state are associated with marked hyperalphalipoproteinemia and absence of significant coronary artery disease. J Mol Med 2006, 84(8):647-650.
90. Ritsch A., Scharnagl H., Eller P., et al. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography. The Ludwigshafen Risk and Cardiovascular Health Study. Circulation 2010, 121:366-374.
91. Robins S.J., Fasulo J.M. High density lipoproteins, but not other lipoproteins, provide a vehicle for sterol transport to bile. J Clin Invest 1997, 99:380-384.
92. Sakai N., Matsuzawa Y., Hirano K., et al. Detection of two species of low density lipoprotein particles in cholesteryl ester transfer protein deficiency. Arterioscler Thromb 1991, 11:71-79.
93. Sandhofer A., Kaser S., Ritsch A., et al. Cholesteryl ester transfer protein in metabolic syndrome. Obesity 2006, 14:812-818.
94. Scanu A.M., Edelstein C. HDL: bridging past and present with a look at the future. FASEB J 2008, 22:4044-4054.
95. Schaefer E.J., Lamon-Fava S., Ordovas J.M., et al. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res 1994, 35:871-882.
96. Schmitz G., Assmann G. Isolation of human serum HDL1 by zonal ultracentrifugation. J Lipid Res 1982, 23:903-910.
97. Schwartz C.C., VandenBroek J.M., Cooper P.S. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res 2004, 45:1594-1607.
98. Scobey M.W., Johnson F.L., Rudel L.L. Delivery of high-density lipoprotein free and esterified cholesterol to bile by the perfused monkey liver. Am J Physiol 1989, 257(4 Pt 1):G644-52.
99. Shetty S., Eckhardt E.R.M., Post S.R., van der Westhuyzen D.R. Phosphatidylinositol-3-kinase regulates scavenger receptor class B type I subcellular localization and selective lipid uptake in hepatocytes. Arterioscler Thromb Vasc Biol 2006, 26:2125-2131.
100. Stevenson S., Wang S., Deng L., Tall A.R. Human plasma cholesteryl ester transfer protein consists of a mixture of two forms reflecting variable glycosylation at Asparagine341. Biochemistry 1993, 32:5121-5126.
101. Sviridov D., Chin-Dusting J., Nestel P., et al. Elevated HDL cholesterol is functionally ineffective in cardiac transplant recipients: Evidence for impaired reverse cholesterol transport. Transplantation 2006, 81:361-366.
102. Takata M., Inazu A., Katsuda S., et al. CETP (cholesteryl ester transfer protein) promoter -1337 C>T polymorphism protects against coronary atherosclerosis in Japanese patients with heterozygous familial hypercholesterolaemia. Clin Sci (Lond) 2006, 111(5):325-331.
103. Tanigawa H., Billheimer J.T., Tohyama J., Zhang Y., Rothblat G., Rader D.J. Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport. Circulation 2007, 116(11):1267-1273.
104. Tchoua U., D'Souza W., Mukhamedova N., et al. The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport. Cardiovasc Res 2008, 77:732-739.
105. Teh E.M., Dolphin P.J., Breckenridge W.C., Tan M.H. Human plasma CETP deficiency: identification of a novel mutation in exon 9 of the CETP gene in a Caucasian subject from North America. J Lipid Res 1998, 39:442-456.
106. Thompson A., Angelantonio E.D., Sarwar N., et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. J Am Med Assoc 2008, 299:2777-2788.
107. Thompson J.F., Reynolds J.M., Williams S.P., Wood L.S., Paciga S.A., Lloyd D.B. Frequency and function of CETP variants among individuals of Asian ancestry. Atherosclerosis 2009, 202:241-247.
108. Trigatti B., Rayburn H., Vinals M., et al. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc Natl Acad Sci USA 1999, 96:9322-9327.
109. Vaisar T., Pennathur S., Green P.S., et al. Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of HDL. J Clin Invest 2007, 117:746-756.
110. Van der Hoorn J.W.A., de Haan W., Berbee J.F.P., et al. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE-3Leiden. CETP mice. Arterioscler Thromb Vasc Biol 2008, 28:2016-2022.
111. van der Steeg W.A., Holme I., Boekholdt S.M., et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: Significance for cardiovascular risk. J Am Med Assoc 2008, 51:634-642.
112. Van Eck M., Hoekstra M., Hildebrand R.B., et al. Increased oxidative stress in scavenger receptor BI knockout mice with dysfunctional HDL. Arterioscler Thromb Vasc Biol 2007, 27:2413-2419.
113. Vasan R.S., Pencina. M.J., Robins S.J., et al. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation 2009, 120:2414-2420.
114. Vreugdenhil A.C.E., Snoek A.M.P., van't Veer C., Greve J.W.M., Buurman W.A. LPS-binding protein circulates in association with apoB-containing lipoproteins and enhances endotoxin-LDL/VLDL interaction. J Clin Invest 2001, 107:225-234.
115. Wang S., Wang X., Deng L., Rassart E., Milne R.W., Tall A.R. Point mutagenesis of carboxyl-terminal amino acids of cholesteryl ester transfer protein. J Biol Chem 1993, 268:1955-1959.
116. Wang X., Driscoll D.M., Morton R.E. Molecular cloning and expression of lipid transfer inhibitor protein reveals its identity with apolipoprotein F. J Biol Chem 1999, 274:1814-1820.
117. Watts G.F., Ji J., Chan D.C., et al. Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome. Clin Sci 2006, 111:193-199.
118. Williams P.T. High-density lipoprotein cholesterol and other risk factors for coronary heart disease in female runners. N Engl J Med 1996, 334:1298-1303.
119. Wilson H.M., Patel J.C., Russell D., Skinner E.R. Alterations in the concentration of an apolipoprotein E-containing subfraction of plasma high density lipoprotein in coronary heart disease. Clin Chim Acta 1993, 220:175-187.
120. Ye D., Kraaijeveld A.O., Grauss R.W., et al. Reduced leucocyte cholesteryl ester transfer protein expression in acute coronary syndromes. J Intern Med 2008, 246:571-585.
121. Yvan-Charvet L., Matsuura F., Wang N., et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol 2007, 27:1132-1138.
122. Yvan-Charvet L., Pagler T.A., Wang N., et al. SR-BI inhibits ABCG1-stimulated net cholesterol efflux from cells to plasma HDL. J Lipid Res 2008, 49:107-114.
123. Zhang A., Gao S., Fan J., Huang W., Zhao T., Liu G. Increased plasma HDL cholesterol levels and biliary cholesterol excretion in hamsters by LCAT overexpression. FEBS Letters 2004, 570:25-29.
124. Zhang X., Moor A., Merkler K., Liu Q., McLean M. Regulation of alternative splicing of liver scavenger receptor class B gene by estrogen and the involved regulatory splicing factors. Endcrinology 2007, 148:5295-5304.